- Home
- OP vs AIM Comparison
OP vs AIM Comparison
Compare OP & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- AIM
- Stock Information
- Founded
- OP 2021
- AIM 1966
- Country
- OP Greece
- AIM United States
- Employees
- OP N/A
- AIM N/A
- Industry
- OP
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OP
- AIM Health Care
- Exchange
- OP Nasdaq
- AIM Nasdaq
- Market Cap
- OP 8.3M
- AIM 9.8M
- IPO Year
- OP N/A
- AIM N/A
- Fundamental
- Price
- OP $1.07
- AIM $0.14
- Analyst Decision
- OP
- AIM Strong Buy
- Analyst Count
- OP 0
- AIM 2
- Target Price
- OP N/A
- AIM $2.75
- AVG Volume (30 Days)
- OP 9.9K
- AIM 1.5M
- Earning Date
- OP 04-10-2025
- AIM 04-01-2025
- Dividend Yield
- OP N/A
- AIM N/A
- EPS Growth
- OP N/A
- AIM N/A
- EPS
- OP N/A
- AIM N/A
- Revenue
- OP $25,729,000.00
- AIM $190,000.00
- Revenue This Year
- OP N/A
- AIM N/A
- Revenue Next Year
- OP N/A
- AIM $1,693.10
- P/E Ratio
- OP N/A
- AIM N/A
- Revenue Growth
- OP 36.33
- AIM N/A
- 52 Week Low
- OP $1.02
- AIM $0.12
- 52 Week High
- OP $3.15
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- OP 34.21
- AIM 36.62
- Support Level
- OP $1.04
- AIM $0.12
- Resistance Level
- OP $1.18
- AIM $0.21
- Average True Range (ATR)
- OP 0.04
- AIM 0.02
- MACD
- OP -0.00
- AIM -0.00
- Stochastic Oscillator
- OP 21.43
- AIM 22.88
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.